Hypofractionated whole breast irradiation: new standard in early breast cancer after breast-conserving surgery.
Hypofractionated whole breast irradiation (HF-WBI) has been proved effective and safe and even better for late or acute radiation toxicity for early breast cancer. Moreover, it improves patient convenience, quality of life and is expected to be advantageous in the medical care system by reducing overall cost. In this review, we examined key randomized trials of HF-WBI, focusing on adequate patient selection as suggested by the American Society of Therapeutic Radiology and Oncology (ASTRO) guideline and the radiobiologic aspects of HF-WBI in relation to its adoption into clinical settings. Further investigation to identify the current practice pattern or cost effectiveness is warranted under the national health insurance service system in Korea.
Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.
Kyung Su
KS
Kim
Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.
Kyung Hwan
KH
Shin
Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.
Noorie
N
Choi
Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.|Department of Radiation Oncology, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea.
Sea-Won
SW
Lee
Breast neoplasms; Dose hypofractionation; Radiotherapy